Compare Neurocrine Biosciences Inc (NBIX) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs VanEck Semiconductor ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while VanEck Semiconductor ETF trades at $584.06. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | SMH | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | — |
52-Week High | $180.55 | $668.91 |
52-Week Low | $123.10 | $283.95 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SMH trades at $584.08, up 5.08% in the last 24 hours, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The semiconductor ETF faces mixed sentiment as AI-driven chip stocks correct despite strong Q2 earnings. Recent institutional buying by firms like Empirical Wealth Management and Assetmark Inc. contrasts with broader market concerns about semiconductor sector rotation and China's potential export controls on AI technologies.
Near-term outlook remains cautious due to technical bearish signals and sector volatility, though oversold RSI levels suggest potential for a rebound. Key risks include geopolitical tensions, AI capex slowdown fears, and concentrated portfolio exposure. The ETF's performance hinges on semiconductor earnings momentum and hyperscaler spending trends through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
